Navigation Links
Immune Targeting Systems and WCCT Global Announce a New Influenza A H1N1 Virus to Support the Experimental Human Viral Challenge Model
Date:8/18/2014

CYPRESS, Calif. and LONDON, Aug. 18, 2014 /PRNewswire-iReach/ -- Immune Targeting Systems (ITS), specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A. To determine the effectiveness of FlunisynTM ITS produced its own live influenza challenge agent derived from the recently circulating Influenza A/California/2009 (H1N1) virus. This challenge virus, manufactured in compliance with the high level of quality and characterization required by the U.S. FDA and other Regulatory Agencies, has a much better infectivity profile than reported for similar challenge viruses.   Whilst the main purpose in developing its own challenge virus was to advance the development of FlunisynTM and to further understand the natural course of influenza illness, ITS wants to make the virus available to enable and support the development of new antiviral drugs and vaccines.

Photo - http://http://photos.prnewswire.com/prnh/20140815/136447

Immune Targeting Systems announced today an asset purchase agreement with WCCT Global (WCCTG) for ITS' proprietary developed challenge strain. Through this partnership, WCCTG has become the only commercial company offering sponsors the ability to do large scale influenza challenge studies in the United States.  The Experimental Human Viral Challenge Model has become widely accepted as an alternative to traditional early stage field trials to show the efficacy of antiviral and vaccine therapies.    The WCCTG facility in Costa Mesa, California, has been completely reconfigured to provide private rooms, separate ventilat
'/>"/>

SOURCE WCCT Global
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
2. Novimmune Reports Successful Completion of Phase I trial for NI-0101
3. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
4. UMD Researcher Helps Arm the Immune System to Fight Cancer
5. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
6. BHI Elects MedImmunes Reg Seeto, M.D. to Board of Directors
7. Global Autoimmune Disease Diagnostics Market
8. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
9. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
10. Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
11. Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... NEW YORK , May 4, 2015  FireflySci Inc., the newest member of the ... months after launch, they have turned the cuvette industry on its head by offering scientists amazing ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
(Date:5/4/2015)... 2015 Sheltering Arms announced that it ... House. The Mother Hale Learning Center meets a tremendous ... Education. Sheltering Arms will begin operating the site immediately ... by the center. , Opened in 2006, the Mother ... to five years, many of whom come from high-need ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running Camps are focused ... educate first and train second, with a significant amount of time ... are building the knowledge base needed to have a long and ... Effort Based Training, Running Heroes, Running Vocabulary, and Why am I ... not a camp where kids come to run and train hard ...
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional ... levels, Astroglide TTC™ is specially formulated to provide a ... Centers for Disease Control, an average of one ... sustaining a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Fast on ... Gladen’s documentary Trace Amounts, and Allison Folmar, JD, join ... conference held internationally. , On Sunday, May 24, the ... from autism possible?" Are you interested in Ryan Hinds' ... There: winning our war against autism was written ...
Breaking Medicine News(10 mins):Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4
... an attempt to tackle the global threat from bird ... as it is felt that// it may provide the ... to set up such a system has been published ... surveillance measures through co-ordination between such international labs can ...
... supplementation during pregnancy can reduce the incidence of ... study published by American Journal of Obstetrics and ... by elevated blood pressure and proteinuria (high levels ... feet, hands and legs is usually seen. If ...
... to spread awareness about AIDS/HIV, the Rotarians of Malda ... a health awareness program// ('One step for awareness about ... barbers. ,The local barbers, under the guidance ... AIDS/HIV awareness session was conducted at Rotary Bhawan. The ...
... A study carried in eight Ethiopian villages for two years ... to nip infection causing trachoma, which happens to be the// ... one Tanzanian village had seemed to show that a single ... the infection. A new study has suggested that the infection ...
... great grandfather at 79 and a war veteran, having braved ... met his end at the hands of a// nurse, who ... to give him a good night’s sleep. ,Hull Crown ... Heaton, aged 79 by giving him a sedative injection that ...
... widely prescribed by the physicians to those in the ... abnormal heart rhythm. They are less commonly given to ... the highest. In case of elders also those who ... prescribed warfarin when they are discharged. The study results ...
Cached Medicine News:Health News:Warfarin the Not So Popular Drug for Stroke 2
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
For the quantitative in vitro determination of Apolipoprotein A-1 in human serum....
For the quantitative determination of apolipoprotein B (apo B) in serum and plasma....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
Medicine Products: